// App-Quantinova.ai

3831 : Oncogenic BRAF and concomitant RAS or PTEN/PI3K mutations determine together the response to RAS/RAF/PI3K signaling network inhibition

Researchers

Presenter

  • Tamas M. Garay

Principal Investigators

  • Eszter Molnar

  • Dominika Rittler

  • Walter Berger

  • Balazs Dome

  • Jozsef Timar

  • Balazs Hegedus

Medical Centers

  • Brain Metastasis Research Group, Hungarian Academy of Sciences and Semmelweis University, Budapest, Hungary

  • Semmelweis University, nd Department of Pathology, Budapest, Hungary

  • Institute of Cancer Research, Medical University of Vienna, Wien, Austria

  • National Koranyi Institute of TB and Pulmonology, Budapest, Hungary.

Locations

  • Austria

  • Hungary

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

  • Melanoma

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved